This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KITAJIMA, N. Articles by FUJITA, T. Search for Related Content PubMed PubMed Citation Articles by KITAJIMA, N. Articles by FUJITA, T.

Effects of Dopamine on Immunoreactive Growth Hormone-Releasing Factor and Somatostatin Secretion from Rat Hypothalamic Slices Perifused in Vitro^*

Third Division, Department of Medicine, and Division of Metabolism and Nutrition, International Center for Exchanging Medical Research (K.C., Y.O.), Kobe University School of Medicine Kobe 650
Kobe University School of Allied Medical Sciences (M. W.) Kobe 645-01, Japan

Address all correspondence and requests for reprints to: Dr. Kazuo Chihara, Division of Metabolism and Nutrition, International Center for Exchanging Medical Research, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650, Japan.

Abstract

The effects of dopamine (DA) on the release of GRF and somatostatin (SRIF) from the hypothalami of adult male rats were examined in an in vitro perifusion system using horizontal hypothalamic slices, 400 fim thick, including the median eminence and arcuate nuclei. When hypothalamic slices from five animals were perifused in a chamber with artificial cerebrospinal fluid (ACSF) at a flow rate of 100 µl/min under a gaseous phase of 95% O2 and 5% CO2 at 37 C, rat (r) GRF- and SRIF-like immunoreactivities (-LI) were constantly detected in 30-min perifusates at least until 240 min of perifusion, and during the perifusion with 60 mM K⁺, the concentrations of rGRF-LI and SRIF-LI were increased 2.1 and 3.2 times, respectively, over basal values. Under the perifusion with ACSF containing normal goat -globulin, the addition of 1O^-8 M DA resulted in a significant increase in SRIF-LI from 8.2 ± 0.3 to 14.3 ± 1.5 pg/hypothalamus · 30 min, but conversely, it caused a slight but significant decrease in rGRF-LI from 4.5 ± 0.9 to 2.0 ± 0.3 pg/hypothalamus · 30 min. On the other hand, 10"8 and 10-6 M DA significantly stimulated rGRF-LI release from hypothalamic slices perifused with ACSF containing anti-SRIF goat 7-globulin. These findings suggest that DA is a secretagogue for both SRIF and rGRF in the hypothalamus, but the rGRFstimulating effect of DA is masked unless the action of endogenous SRIF is attenuated. (Endocrinology 124: 69–76, 1989)

Footnotes

^* This work was supported in part by research grants from the Japanese Ministry of Health and Welfare; the Japanese Ministry of Education, Science, and Culture; and the Growth Science Foundation for 1987.

Received June 15, 1988.

This article has been cited by other articles:

				G. Diaz-Torga, C. Feierstein, C. Libertun, D. Gelman, M. A. Kelly, M. J. Low, M. Rubinstein, and D. Becu-Villalobos Disruption of the D2 Dopamine Receptor Alters GH and IGF-I Secretion and Causes Dwarfism in Male Mice Endocrinology, April 1, 2002; 143(4): 1270 - 1279. [Abstract] [Full Text] [PDF]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]